Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1001-1020 of 1,743 trials

Cardiac Surgery: Fibrinogen Concentrate Study

We are testing a new treatment to manage bleeding in patients undergoing complex cardiac surgery. The goal is to see if it reduces the need for blood transfusions compared to a placebo.

Functional Disturbances After Cardiac SurgeryBleeding in Cardiac Surgery Patients>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

IKS03 for Advanced B Cell Non-Hodgkin Lymphoma

We are studying the effects of IKS03 in patients with advanced B cell non-Hodgkin lymphoma. The goal is to see if it can improve treatment outcomes compared to standard therapies.

Advanced B cell Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Oncology

Soft Tissue Sarcomas: INT230-6 Treatment Study

We are investigating a new treatment for adults with advanced soft tissue sarcomas to see if it works better than standard care. The study will also look at side effects and quality of life for participants.

Myxoid LiposarcomaDedifferentiated LiposarcomaRound Cell Liposarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Gastrointestinal Cancers: Patritumab Deruxtecan Study

We are evaluating a new treatment for people with gastrointestinal cancers to see if it is safe and effective. This study aims to understand how well it works compared to existing options.

Colorectal CancerHepatocellular CarcinomaBiliary Tract Cancer>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesOncology

Organ Transplantation: Custodiol-N vs. Custodiol Solution

We are studying a new preservation solution for kidney, liver, and pancreas transplants to see if it works as well as the current standard. This research may help improve outcomes for transplant recipients.

Organ Transplant Candidates>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesEndocrinologyHepatologyInternal MedicineNephrologyOrthopedics and Traumatology

Bevacizumab vs. Corticosteroids for Cerebral Radiation Necrosis

We are studying whether bevacizumab is more effective than corticosteroids for treating symptoms of cerebral radiation necrosis in patients with high-grade glioma or brain metastases. The trial also looks at quality of life and other health impacts.

Brain MetastasesHigh-Grade Glioma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncology

ANCA Vasculitis: Stopping Immunosuppressive Therapy

We are studying whether stopping immunosuppressive therapy helps patients with ANCA vasculitis and end-stage renal disease avoid serious health issues compared to continuing treatment.

End-stage Renal DiseaseANCA Vasculitis>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesNephrologyRheumatology

CRISPR CAR Therapy for Blood and Solid Cancers

We are studying the long-term safety and effectiveness of CRISPR CAR cellular therapies in patients with hematological and solid malignancies. This research aims to provide insights into how well this treatment works over time.

Solid TumorsHematologic Malignancies>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Cardiovascular Disease: Low Dose Rivaroxaban in Advanced CKD

We are studying whether a low dose of rivaroxaban can help reduce serious heart-related events in people with advanced chronic kidney disease or on dialysis. This trial compares the medication to a placebo to see if it offers any benefits.

Heart and Kidney Disease>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementCardiologyNephrology

Pancreatic Cancer: New Electroporation Treatments

We are studying the effects of three innovative treatments for pancreatic cancer to see if they improve quality of life and survival. This includes assessing pain levels and weight loss in patients.

Unresectable Pancreatic Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Liver Cancer: Hyperpolarized Pyruvate MRI Study

We are exploring whether a new MRI technique can help detect small liver tumors earlier in people at risk for hepatocellular carcinoma. This may improve early diagnosis and treatment options.

Primary Liver Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInternal Medicine

Chronic Kidney Disease: Ultra-Sensitive MRI Study

We are investigating how advanced MRI can detect metabolic changes in patients with chronic kidney disease and polycystic kidney disease. This research may help improve diagnosis and treatment monitoring.

Autosomal Dominant Polycystic Kidney Disease (ADPKD)Chronic Kidney Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNephrology

Glioblastoma: Dendritic Cell Vaccine Study

We are testing a personalized vaccine made from your own immune cells and tumor tissue for patients with glioblastoma. The study aims to see if this treatment can improve safety and help patients live longer without disease progression.

Glioblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Plaque Psoriasis: TAK-279 Oral Medication

We are studying a new daily oral treatment for people with moderate-to-severe plaque psoriasis. The trial will help us understand its long-term safety and effectiveness.

Plaque Psoriasis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Advanced Cancer: BI 1831169 and Anti-PD-1 Therapy

We are testing different doses of a new medication alone and with an anti-PD-1 antibody for people with advanced solid tumors. This study aims to see how well these treatments work together.

Solid Tumors>2 yearsSafety phase (I)Oncology

CIDP Treatment: Rituximab Study

We are investigating whether adding Rituximab to IVIg treatment can help people with CIDP achieve long-term remission. This may reduce the need for regular infusions and associated healthcare costs.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Botox for Inability to Belch

We are studying whether Botox injections into the upper esophageal sphincter can help people who struggle to belch. This trial compares the effects of Botox with a placebo to assess symptom improvement.

Esophageal Disorders>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyOtolaryngology

Muscle-Invasive Bladder Cancer: Erdafitinib Treatment Study

We are studying the effects of erdafitinib alone and with cetrelimab in patients with muscle-invasive bladder cancer who cannot take cisplatin. The goal is to see if this treatment can shrink tumors before surgery.

Muscle-Invasive Bladder Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyUrology

HER2-Positive Gastric Cancer: Rilvegostomig Treatment Study

We are comparing a new treatment combining rilvegostomig with other medications to standard therapies for patients with HER2-positive gastric cancer. The goal is to see if this new approach improves survival and reduces disease progression.

HER2-positive Gastric Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Gene Therapy for Hearing Loss: AAVAnc80-hOTOF

We are studying a new gene therapy for people with hearing loss due to Otoferlin gene mutations. The trial aims to assess the long-term safety and effectiveness of this treatment.

Otoferlin Gene-Mediated Hearing Loss>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineNeurologyOtolaryngology